Drug That Boosts Immunotherapy Studied as Tool to Battle COVID-19 in Patients With Cancer
An investigational drug, IMM-101, already being studied for its ability to increase the effects of immuno-oncology agents, may be able to prevent or lessen the effects of COVID-19 among those with cancer.
Too Much, Too Fast: Providers Push Back on CMS’ Final RO Model
A discussion of the final Radiation Oncology Model; after this article went to press, CMS announced a delay until July 2021, reflecting concerns of radiation oncologists.
Connecting the Dots
Creativity is just connecting things--Steve Jobs
Uncertainty From COVID-19 Delays Progress on the Road to Value-Based Cancer Care
COVID-19 has created a significant distraction from normal practice operations. The uncertainty that comes along with the pandemic is a huge worry, and can distract from practice transformation.
Three Ways COVID-19 Makes the Oncology Care First Model More Attractive
COVID-19 has delayed the transition to Oncology Care First, but the forthcoming model could help.
Understanding the Challenges of Rural Cancer Care
A look at the special challenges of delivering cancer care in rural areas, as ASCO seeks to address this issue.
When the Topic Is Dying: A Conversation With Kashyap Patel, MD
Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, associate editor of Evidence-Based Oncology, and vice president of the Community Oncology Alliance, discusses his new book.
Being Each Other’s Hero: Facing MBC Together
At diagnosis, approximately 6% of breast cancers are metastatic breast cancer (MBC), which although treatable is not curable. Experts predicted that 276,480 women and 2620 men would receive such a diagnosis in 2020.
2 Clarke Drive Cranbury, NJ 08512